Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01471067 Background | Jul 2012 → Apr 2017 | disease related to hematopoietic stem cell transplant, leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01471067 ↗ |
| Action | Deplete | “Anti-thymocyte globulin (ATG) is a protein that removes immune cells that cause damage to the body.” NCT01471067 ↗ |
| Modality | Protein / enzyme biologic | “Anti-thymocyte globulin (ATG) is a protein that removes immune cells that cause damage to the body.” NCT01471067 ↗ |
| Route | Intravenous | “1.25 mg/Kg by vein on Day -4.” NCT01471067 ↗ |